The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies

The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies Early and sustained treatment of patients with MS with a high efficacy therapy delays disability progression and the time to reaching key long-term disability milestones. OCR has a robust long-term safety and efficacy experience across the MS spectrum. Results for OCR over eleven years are reported for 48-week CDP and other measures of progression (including the rate of repeated 48-week CDP, and the time to requiring walking aid or wheelchair) during OPERA I/II (NCT01247324/NCT01412333), ORATORIO (NCT01194570) and their open-label extensions. https://medically.roche.com/global/en/medical-material.7539ff6d-3fbb-422c-bd07-6b2f2616a529.qr.html?cid=slpsectrims20242409xxnvspht